|
The
pharmaceutical division is a world leader in discovery, development,
manufacturing and marketing of prescription medicines. Our goal is
to provide a broad portfolio of innovative, effective and safe
products and services to patients through healthcare professionals
around the world. Innovation is at the heart of all our strategies
and development. Our 8 major research sites in 3 continents gives us
the cutting edge to introduce medical solutions to unmet medical
needs across the globe and gives us the advantage to offer
ground-breaking new medicines to Bangladesh.
In Bangladesh we have been offering innovative global brands since
inception. Our particular focus is on cardiovascular disease,
oncology, gastrointestinal, dermatological disorders and respiratory
illnesses.
In Bangladesh we have our focus on the following Business Units:
Cardiovascular & Metabolism
Our broad portfolio of cardiovascular and metabolic agents offers
some of the best tools available today to treat and protect patients
along critical points of the cardio-metabolic disease continuum.
Our top products include Diovan,
Co-Diovan/Diovan HCT and Lotrel for the treatment of high blood
pressure and other cardiovascular conditions, as well as the
cholesterol-lowering agent Lescol. Our leading development compounds
are Tekturna/Rasilez and Exforge for hypertension and Galvus for
type 2 diabetes.
Oncology & Hematology
The strong oncology portfolio of Novartis provides a broad
range of innovative therapies and practical solutions for
cancer patients. Our efforts to discover and develop
innovative approaches for the treatment of cancer have
produced breakthrough medicines such as the leukemia therapy
Gleevec/Glivec and the breast cancer agent Femara as well as
Zometa for the treatment of bone
cancers. Our leading compounds in de velopment are Tasigna
for chronic myeloid leukemia (CML), RAD001 (everolimus) for
various tumors and SOM230 (pasireotide) for Cushing’s
disease.
Neuroscience
An innovator in the field of neuroscience for more than 50
years, Novartis pioneered early breakthrough treatments for
disorders of the central nervous system including
Alzheimer's disease, Parkinson's disease, epilepsy,
depression, migraine, attention deficit/hyperactivity
disorder and schizophrenia. Leading products include Exelon
for the treatment of Alzheimer's disease and dementia
associated with Parkinson’s disease, the anti-epileptic
Trileptal, and Stalevo for the treatment of Parkinson’s
disease. Our leading development compounds are FTY720 (fingolimod)
for patients with relapsing multiple sclerosis, Exelon Patch
for Alzheimer’s disease and AGO178 (agomelatine) for
depression.
Respiratory
One of our leading products is Xolair for the treatment of
severe allergic asthma, and we are making investments in new
medicines for respiratory diseases such as chronic
obstructive pulmonary disease (COPD). Our leading
development compound is QAB149 (indacaterol), which provides
the cornerstone for an ambitious program to develop a range
of once-daily inhaled therapies.
Infectious Diseases, Transplantation & Immunology (IDTI)
This therapeutic area combines our leadership in
transplantation and immunology with the growth potential of
our infectious diseases pipeline. Our ambition in hospital
infections is to address serious needs for life-threatening
infections and our goal is also to achieve a leadership
position in hepatitis. Tyzeka/Sebivo, a potent treatment for
chronic hepatitis B, is being launched in several countries.
One of our leading development compounds targeting hepatitis
C, ABF656 (Albuferon®), has just entered Phrase III studies.
Novartis pioneered and revolutionized the field of
transplantation with the discovery of cyclosporine more than
20 years ago and offers a comprehensive portfolio to support
organ transplantation.
Ophthalmics, Dermatology, Gastrointestinal, Urinary (ODGU)
In ophthalmics, Visudyne and Lucentis are treatments for
“wet,” age-related macular egeneration (AMD), the top cause
of vision loss in people over age 50. Key dermatology
products are Elidel for eczema and Lamisil for fungal nail
infections. Zelnorm/Zelmac helps patients with irritable
bowel syndrome and chronic constipation, while Enablex/Emselex
is for urinary incontinence.
Arthritis & Bone
Novartis is committed to developing and offering new
therapies to address bone diseases such as osteoporosis, as
well as painful conditions related to the skeletal system,
particularly osteoarthritis. Aclasta/Reclast is the leading
compound in development for patients with osteoporosis. In
osteoarthritis, the selective COX-2 inhibitor Prexige
recently received approval in Europe and is approved in over
50 countries.
|
